



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

OCT 15 1998

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Ms. Eileen McCafferty
Regulatory Affairs Manager
Shield Diagnostics Limited
The Technology Park
Dundee DD2 1XA UK

Re: K982879
Trade Name: Shield DIASTAT anti- β_2 Glycoprotein 1 IgG (ELISA)
Assay
Regulatory Class: II
Product Code: MSV
Dated: August 11, 1998
Received: August 14, 1998

Dear Ms. McCafferty:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Page 1 of 1510(k) Number (if known): ~~NOT KNOWN~~ K982879Device Name: DIASTAT anti- β_2 GLYCOPROTEIN 1 IgG ELISA TEST

Indications for Use: The Diastat anti- β_2 Glycoprotein1 IgG Test is a semi-quantitative enzyme immunoassay for the detection, in human serum or plasma (citrate or EDTA anticoagulated), of the IgG class of autoantibodies specific for β_2 GP1 Antigen. The test is intended for use as an aid in the assessment of thrombotic risk in patients with autoimmune disease associated with thrombotic disorders such a primary anti-phospholipid syndrome, or secondary to Systemic Lupus Erythematosus. The test results are not definitive in isolation and represent one parameter in a multi-criterion diagnostic process. The option of a qualitative protocol is also available.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number

K982879Prescription Use ☒
(Per 21 CFR 801.109)

OR

Over-The -Counter Use _____